Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development
Dr. Miller, 56, brings over 25 years of experience in biopharmaceuticalproduct research and preclinical development to his new position. Prior tojoining Insmed, he served as Executive Vice President of Product Developmentat Saronyx, Inc., a private life sciences company that he also co-founded.Dr. Miller earlier held senior development, operations and research positionsat both Reneneron Pharmaceuticals, Inc., and Amgen. His strategic andmanagement expertise, which center around the biopharmaceutical developmentprocess, includes team management, research design and implementation,strategic planning, product development, and product marketing.
Dr. Miller received his Ph.D. in Chemistry from the California Instituteof Technology and performed his Postdoctoral work at Yale University School ofMedicine. He has been published on numerous occasions in well-respectedscientific periodicals, including The Journal of Neuroscience, The Archive ofBiochemistry and Biophysics and The Journal of Molecular Biology.
Doug Farrar, Senior Vice President, Manufacturing Operations for Insmedcommented, "We are excited to have Jim join our experienced team. Hisbackground is well suited to further accelerate progress on our follow-onbiologics portfolio as we reach a critical stage in the development process ofthese product candidates."
Dr. Miller commented, "I am pleased to be joining the Insmed team, whichhas consistently demonstrated its advanced knowledge of biologics development,manufacturing capability and its skilled scientific and technical workforce.I am excited to be a part of the first U.S.-based biotechnology company todevelop a comprehensive portfolio of follow-on biologics and look forward toworking with the team to continue advancing these product candidates asrapidly as possible through the development process."
Insmed Inc. is a biopharmaceutical company with unique protein processdevelopment and manufacturing experience and a proprietary protein platformaimed at niche markets with unmet medical needs. For more information, pleasevisit www.insmed.com.
This release contains forward-looking statements which are made pursuantto provisions of Section 21E of the Securities Exchange Act of 1934. Investorsare cautioned that such statements in this release, including statementsrelating to planned clinical study design, regulatory and business strategies,strategic alternatives, plans and objectives of management and growthopportunities for existing or proposed products, constitute forward-lookingstatements which involve risks and uncertainties that could cause actualresults to differ materially from those anticipated by the forward-lookingstatements. The risks and uncertainties include, without limitation, risksthat strategic alternatives may never be consummated, product candidates mayfail in the clinic or may not be successfully marketed or manufactured, we maylack financial resources to complete development of product candidates, theFDA may interpret the results of studies differently than us, competingproducts may be more successful, demand for new pharmaceutical products maydecrease, the biopharmaceutical industry may experience negative markettrends, our entrance into the follow-on biologics market may be unsuccessful,our common stock could be delisted from The NASDAQ Capital Market and otherrisks and challenges detailed in the Company's filings with the U.S.Securities and Exchange Commission, including the Company's Annu
You May Also Like